PHILADELPHIA, PA — EpiVario has announced that its CEO, Thomas Kim, will participate in the prestigious Babson College Substance Use Disorder (SUD) Sprint program. Kim is among 30 innovators selected for the 2024 cohort, which is sponsored by the National Institute on Drug Abuse (NIDA).
In August, these experts will convene in Massachusetts for a five-day, in-person strategic workshop. The program is built on Babson’s Entrepreneurial Thought & Action® methodology, designed to foster innovative solutions for substance use disorders. Participants will engage with key industry leaders, visit important sites, and access critical resources while networking with peers.
EpiVario is leading the charge in researching cue-triggered drug cravings and relapse prevention. The company focuses on the metabolic enzyme acetyl CoA synthetase-2 (ACSS2), which plays a pivotal role in the formation of cocaine-related memories. EpiVario’s approach aims to develop acute treatments that diminish drug craving responses and help prevent relapse in patients suffering from SUD.
“I am excited about this opportunity to work with other entrepreneurs and experts in the field to address the substance use crisis in the United States,” said Kim. “This selection highlights the value of EpiVario’s approach to treating these disorders.”
The Babson College SUD Sprint program promises to be a transformative experience, contributing to the advancement of effective treatments for substance use disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.